Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Mass General Brigham Cancer Institute at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Mass General Brigham Cancer Institute brings 2 presentations to SITC 2026 in Phoenix. Its program centres on new combination treatments in melanoma and breast cancer. One study maps tumor-immune niches linked to response when an mRNA therapy is given with pembrolizumab, and another reports early results for invikafusp alfa with sacituzumab govitecan in metastatic breast cancer.

Organization	SITC 2026 Attendance
Mass General Brigham Cancer Institute Boston, MA
massgeneralbrigham.org Cancer centres & hospitals Cancer institute coordinating cancer care and research across Mass General Brigham.	Plenary Fri Nov 6 10:24am–10:37am Part of Session 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future Spatial profiling identifies response-associated tumor-immune niches and treatment-induced remodeling with mRNA-4359 plus pembrolizumab in melanoma Halls BC Vaccines · Biomarkers Talk Sat Nov 7 4:18pm–4:33pm Part of Session 206e: Oral Abstract Session 3 Initial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC 301D Clinical · New agents

Organization

SITC 2026 Attendance

Mass General Brigham Cancer Institute

Boston, MA

massgeneralbrigham.org

Cancer centres & hospitals

Cancer institute coordinating cancer care and research across Mass General Brigham.

Plenary

Fri Nov 6
10:24am–10:37am

Part of Session 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future

Spatial profiling identifies response-associated tumor-immune niches and treatment-induced remodeling with mRNA-4359 plus pembrolizumab in melanoma

Halls BC